Inventiva SA

IVA · NYSE

$3.71+$0.11 (+3.06%)TodayMarket closed · Oct 23, 7:24 PM ET

Prev close $3.60

IVA analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $14.14 (+281.1% upside)

Low: $7.60
Now: $3.71
High: $26.78

Upgrades and downgrades

The latest rating actions, newest first

IVA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Oct 2, 2026	Maintains	Buy	$13.00 → $18.00	54%
Canaccord Genuity	Sep 29, 2026	Maintains	Buy	$20.00 → $21.00	49%
Guggenheim	Sep 15, 2026	Maintains	Buy	$11.00 → $14.00	60%
Cantor Fitzgerald	Jul 17, 2026	Initiates	Overweight	—	39%
Truist Securities	Mar 19, 2026	Initiates	Buy	$13.00	54%
Barclays	Jan 28, 2026	Initiates	Overweight	$18.00	48%
Leerink Partners	Jan 12, 2026	Initiates	Outperform	$12.00	25%
UBS	Jan 7, 2026	Initiates	Neutral → Buy	$3.00 → $12.00	54%
Guggenheim	Nov 18, 2025	Maintains	Buy	$13.00 → $11.00	60%
Wolfe Research	Nov 6, 2025	Initiates	Outperform	$13.00	48%

The case for and against

Updated Oct 22, 2026

Bull case

Inventiva is supported by a differentiated pan-PPAR mechanism in lanifibranor that targets metabolic drivers, inflammation, and fibrotic remodeling, while its Phase 2b NATIVE data already showed 24% placebo-adjusted response on the composite endpoint and 18% fibrosis improvement at 6 months. Management and analysts view those results as a credible bar for Phase 3 NATiV3, especially since the trial is longer at 72 weeks, enriched with about 55% T2D patients and more F3 disease, and has shown dropout rates below 30%, which supports statistical durability. The company also has a sizable commercial opportunity in MASH, with projected worldwide peak adjusted revenue of €2.4B/$2.7B and longer-term U.S. risk-adjusted sales forecast around $3.2B by 2035, while partnerships and IP through 2041 add strategic optionality.

Bear case

Inventiva is burdened by a clinical and commercial risk profile that remains fragile despite encouraging phase 2b efficacy, because its lead asset still faces phase 3 uncertainty, a prior ~4% discontinuation rate from adverse events, and safety liabilities such as dose-dependent edema and weight gain that could undermine long-term adherence. The bearish case is reinforced by evidence that on-target PPARγ effects may raise fracture and hepatic monitoring concerns, while strong placebo variability and a reported SUSAR case highlight how easily readouts can disappoint or require tighter trial controls. Fundamentally, the company also faces a highly competitive MASH landscape, meaningful pricing pressure, and ongoing financing needs, all of which make dilution and commercialization risk material.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.